Ernexa Therapeutics Inc.
ERNA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 755.9% | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 83.5% | -247.1% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -6,206% | -29,314.7% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,652.7% | -31,864.7% | – | – |
| EPS Diluted | -1.57 | -4.08 | -8.06 | -56.61 |
| % Growth | 61.5% | 49.4% | 85.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |